National Bank Financial Reiterates “C$2.50” Price Target for ImmunoVaccine Inc. (TSE:IMV)

National Bank Financial set a C$2.50 price objective on ImmunoVaccine Inc. (TSE:IMV) in a report released on Wednesday. The brokerage currently has an outperform rating on the stock.

Shares of ImmunoVaccine (TSE IMV) opened at 1.23 on Wednesday. ImmunoVaccine has a 52 week low of $0.57 and a 52 week high of $1.70. The firm’s market capitalization is $148.22 million. The company’s 50 day moving average price is $1.21 and its 200-day moving average price is $1.21.

WARNING: This report was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at

In other ImmunoVaccine news, insider Pierre Labbé acquired 26,825 shares of the stock in a transaction dated Friday, July 28th. The stock was purchased at an average cost of C$1.22 per share, with a total value of C$32,726.50.

ImmunoVaccine Company Profile

Immunovaccine Inc is a Canada-based clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company’s DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications.

What are top analysts saying about ImmunoVaccine Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ImmunoVaccine Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit